RxDoctor Payments Data

Hameed Jahangiri, MD

Psychiatry · Fairfield, CANPI 1497707731

Payments from drug & device makers

$1,262in general payments, 2019–2025

Across 56 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$237
  • Neurocrine Biosciences, Inc.$221
  • Teva Pharmaceuticals USA, Inc.$188
  • Otsuka America Pharmaceutical, Inc.$179
  • Johnson & Johnson$121
  • AbbVie$113
  • plus $202 from 5 others

What the payments were for

  • Food & beverage$1,262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,262 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$19,820
Medicare patients
37
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole40$109,565
Abilify AsimtufiiAripiprazole18$95,733
Invega SustennaPaliperidone Palmitate31$65,930
Paliperidone ErPaliperidone52$7,257
Lurasidone Hcl61$3,709
Aripiprazole75$2,361
Olanzapine OdtOlanzapine23$738
Olanzapine61$663
Divalproex Sodium ErDivalproex Sodium101$628
Divalproex Sodium27$441
Fluoxetine Hcl43$276
Bupropion XlBupropion Hcl15$268
Buspirone Hcl14$253
Risperidone31$237
Quetiapine Fumarate31$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii$179$205,29858 claims
Johnson & JohnsonInvega Sustenna$121$65,93031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Fairfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →